14 recruiting, 9 active not recruiting, 2 suspended, 1 not yet recruiting. 18 Phase 2, 14 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Recruiting 9, Active not recruiting 8, Not yet recruiting 1 |
| Phase 1 | 14 | Recruiting 6, Active not recruiting 4, Suspended 2, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Decitabine and Cedazuridine: new trials by email Literature Review of Decitabine and Cedazuridine trials Research Report on Decitabine and Cedazuridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 126 | 2026-09-25 | 2026-10-21 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-22 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-08-15 | 2026-10-01 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-09-30 |
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-06-12 | 2026-10-22 |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 93 | 2025-05-16 | 2026-10-13 |
| Early Intervention in High Risk CCUS Inqovi - Clonal Cytopenia of Undetermined Significance, Cytopenia | Early Phase 1 | Recruiting | Lachelle D. Weeks, MD, PhD | 108 | 2025-02-07 | 2026-04-23 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-21 |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | Otsuka Beijing Research Institute | 72 | 2023-10-16 | 2026-10-16 |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Suspended | National Cancer Institute (NCI) | 32 | 2023-09-25 | 2026-07-31 |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 132 | 2023-06-27 | 2026-08-19 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Decitabine and Cedazuridine, Entrectinib, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 13 | 2022-10-28 | 2026-10-15 |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS Bisantrene Dihydrochloride (high dose), Bisantrene Dihydrochloride (low dose), Cytarabine Hydrochloride - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | Racura Oncology Ltd | 2022-07-29 | 2023-10-03 | |
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2022-02-10 | 2026-10-06 |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer Decitabine and Cedazuridine, Enzalutamide - Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 1 | Terminated | Roswell Park Cancer Institute | 8 | 2022-01-26 | 2025-11-12 |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission Decitabine and Cedazuridine, Enasidenib, Gilteritinib - Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 125 | 2021-10-25 | 2026-10-09 |
Showing 20 of 28. Sign in to see all of them.
Leukemia, Myeloid, Acute (15) · Myelodysplastic Syndromes (8) · Leukemia, Myelomonocytic, Chronic (4) · Myeloproliferative Disorders (3) · Hodgkin Disease (2) · Lymphoma, Large B-Cell, Diffuse (2) · Myelodysplastic-Myeloproliferative Diseases (2) · Anemia, Refractory, with Excess of Blasts (1) · Cytopenia (1) · GATA2 Deficiency (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Polycythemia Vera (1)
National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (7) · Lachelle D. Weeks, MD, PhD (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Otsuka Beijing Research Institute (1) · Racura Oncology Ltd (1) · Roswell Park Cancer Institute (1) · University of Washington (1)
United States (25) · Puerto Rico (4) · Canada (2) · Australia (1) · China (1)
Anand A Patel (2) · Abhishek Maiti (1) · Anna Halpern, MD (1) · Catherine S Diefenbach (1) · Courtney DiNardo, MD (1) · Elias Jabbour (1) · Eric J Huselton (1) · Evan C Chen (1) · Farhad Ravandi-Kashani (1) · Farhad Ravandi-Kashani, MD (1) · Guillermo Garcia-Manero (1) · Gurkamal S Chatta (1) · Jerald P Radich (1) · John L Reagan (1) · Lachelle Weeks, MD (1)
PMID 34552007, PMID 36902217, PMID 38316133, PMID 38452788, PMID 39352751, PMID 40513054, PMID 42013378
U10CA180888 (3), UM1CA186689 (3), U10CA180821 (2), UM1CA186709 (2), P01CA229086 (1), P30CA016087 (1), P50CA097274 (1), UM1CA186686 (1), UM1CA186717 (1), UM1CA228823 (1)